Trials / Unknown
UnknownNCT00002454
Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx
Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- University of Medicine and Dentistry of New Jersey · Academic / Other
- Sex
- All
- Age
- 1 Year
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Vaccines made from papilloma virus cells may make the body build an immune response to and kill papilloma cells. PURPOSE: Phase II trial to study the effectiveness of papilloma virus vaccine in treating young patients with recurrent papilloma of the larynx.
Detailed description
OBJECTIVES: I. Determine the immune response in patients with juvenile papilloma of the larynx treated with autogenous vaccine derived from each patient's own tumor. OUTLINE: Patients receive autogenous papilloma vaccine intradermally and subcutaneously weekly for 20 weeks. PROJECTED ACCRUAL: Not specified
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | autologous tumor cell vaccine |
Timeline
- Start date
- 1971-12-01
- First posted
- 2004-02-27
- Last updated
- 2011-07-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00002454. Inclusion in this directory is not an endorsement.